Celldex Therapeutics

Three darts hitting bullseye
Biotech

Celldex monoclonal antibody rebounds with pair of phase 3 wins

The trials met both primary and secondary endpoints, giving Celldex’s barzolvolimab a chance at redemption after its recent phase 2 flop.
Marissa Russo Sep 22, 2026 10:30am
Goal disorientation and lack of vision

Celldex ends skin disease program after failing phase 2 test

Jul 22, 2026 6:00am
Chutes Ladders Canada British columbia

Ovid eyes next chapter with CEO transition—Chutes & Ladders

Nov 14, 2025 8:30am
Goal disorientation and lack of vision

Celldex ends esophageal program despite hitting primary endpoint

Aug 20, 2025 6:42am
reshuffle pipeline target reorganize shift change

Celldex drops phase 1 tumor bispecific to focus on inflammation

Nov 7, 2024 7:25am
target reach ladder climb meet win beat competition

Celldex anti-cKIT antibody reduces hives in another phase 2 test

Jul 30, 2024 5:50am